IP Library › Patent Application 13962094
Patent Application
App. No. 13/962,094

Pharmaceutical Compositions

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/962,094
Abstract

A pharmaceutical composition for inhalation comprising R (+) budesonide and one or more bronchodilators, and, optionally, one or more pharmaceutically acceptable excipients is described.

Claims (42)

1 . A pharmaceutical composition comprising R (+) budesonide and one or more bronchodilators, and, optionally, one or more pharmaceutically acceptable excipients.

2 . A pharmaceutical composition according to claim 1 , wherein R (+) budesonide in an amount ranging from 80-640 mcg.

3 . A pharmaceutical composition according to claim 1 , wherein the bronchodilator comprises one or more beta 2 -agonists.

4 . A pharmaceutical composition according to claim 3 , wherein the beta 2 -agonist is selected from albuterol, levoalbuterol, terbutaline, pirbuterol, procaterol, metaproterenol, fenoterol, bitolterol mesylate, ritodrine, salmeterol, formoterol, arformoterol, carmoterol, bambuterol, clenbuterol, indacaterol, milveterol, vilanterol, olodaterol or a combination thereof.

5 . A pharmaceutical composition according to claim 3 , wherein the beta 2 -agonist comprises formoterol.

6 . A pharmaceutical composition according to claim 3 , wherein the beta 2 -agonist comprises arformoterol

7 . A pharmaceutical composition according to claim 3 , wherein the beta 2 -agonist comprises salmeterol.

8 . A pharmaceutical composition according to claim 3 , wherein the beta 2 -agonist comprises carmoterol.

9 . A pharmaceutical composition according to claim 3 , wherein carmoterol is in an amount ranging from 1 mcg-4 mcg.

10 . A pharmaceutical composition according to claim 3 , wherein the beta 2 -agonist comprises indacaterol.

11 . A pharmaceutical composition according to claim 3 , wherein indacaterol is in an amount ranging from 50 mcg-800 mcg.

12 . A pharmaceutical composition according to claim 1 , wherein the bronchodilator comprises one or more anticholinergics.

13 . A pharmaceutical composition according to claim 12 , wherein the anticholinergic is selected from tiotropium, ipratropium, oxitropium and combinations thereof.

14 . A pharmaceutical composition according to claim 12 , wherein the anticholinergic comprises tiotropium.

15 . A pharmaceutical composition according to claim 12 , wherein tiotropium is in an amount ranging from 9 mcg-18 mcg.

16 . A pharmaceutical composition according to claim 12 , wherein the anticholinergic comprises oxitropium.

17 . A pharmaceutical composition according to claim 12 , wherein the anticholinergic comprises ipratropium.

18 . A pharmaceutical composition according to claim 1 , wherein the bronchodilator comprises one or more beta 2 -agonists and/or one or more anticholinergics.

19 . A pharmaceutical composition according to claim 1 , comprising R (+) budesonide and formoterol.

20 . A pharmaceutical composition according to claim 1 , comprising R (+) budesonide and arformoterol

21 . A pharmaceutical composition according to claim 1 , comprising R (+) budesonide, tiotropium and carmoterol.

22 . A pharmaceutical composition according to claim 1 , comprising R (+) budesonide, tiotropium and indacaterol.

23 . A pharmaceutical composition according to claim 1 , wherein R (+) budesonide and beta 2 -agonists along with any excipients are formulated in a single pharmaceutical composition.

24 . A pharmaceutical composition according to claim 1 , wherein R (+) budesonide and anticholinergics along with any excipients are formulated in a single pharmaceutical composition.

25 . A pharmaceutical composition according to claim 1 , wherein beta 2 -agonists and anticholinergics along with any excipients are formulated in a single pharmaceutical composition.

26 . A pharmaceutical composition according to claim 1 , wherein R (+) budesonide, beta 2 -agonists and anticholinergics along with any excipients are formulated in a single pharmaceutical composition.

27 . A pharmaceutical composition according to claim 1 , formulated as an inhalation composition.

28 . A pharmaceutical composition according to claim 1 , formulated for use in a metered dose inhaler.

29 . A pharmaceutical composition according to claim 27 , further comprising a propellant.

30 . A pharmaceutical composition according to claim 27 , further comprising an excipient selected from a cosolvent, an antioxidant, a surfactant, a bulking agent and a lubricant.

31 . A pharmaceutical composition according to claim 1 , formulated for use as a dry powder inhalation formulation.

32 . A pharmaceutical composition according to claim 31 , further comprising at least one finely divided pharmaceutically acceptable carrier suitable for use in dry powder inhalation formulations.

33 . A combination composition according to claim 32 , wherein said carrier includes a saccharide and/or a sugar alcohol.

34 . A combination composition according to claim 32 , formulated for use as an inhalation solution.

35 . A combination composition according to claim 34 , further comprising an excipient selected from a wetting agent, osmotic agent, a pH regulator, a buffering agent and a complexing agent, provided in a pharmaceutically acceptable vehicle.

36 . A pharmaceutical composition according to claim 1 formulated for inhalation, for use as a nasal spray, for use as nasal drops, for use as an insufflation powder, or for use as a spray patch.

37 . A pharmaceutical composition according to claim 1 for once daily administration.

38 . A pharmaceutical composition according to claim 1 further comprising one or more active(s) selected from antihistamines, antiallergics or leukotriene antagonist or their pharmaceutically acceptable salts, solvates, tautomers, derivatives, enantiomers, isomers, hydrates, prodrugs or polymorphs thereof.

39 . A process for manufacturing a pharmaceutical composition according to claim 1 comprising combining R (+) budesonide with one or more bronchodilators and one or more optional pharmaceutically acceptable excipients.

40 . A method of prophylaxis or treatment of a respiratory, inflammatory or obstructive airway disease, comprising administering a therapeutically effective amount of a pharmaceutical composition according to claim 1 to a patient in need thereof.

41 . A method according to claim 40 , wherein said pharmaceutical composition is administered once daily.

42 . A method according to claim 40 , wherein the disease is COPD or asthma.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 8, 2013
From: MALHOTRA, GEENA; PURANDARE, SHRINIVAS MADHUKAR
To: CIPLA LIMITED
Reel/Frame 030969/0242 →